AstraZeneca (AZN)
(Real Time Quote from BATS)
$85.01 USD
+1.24 (1.48%)
Updated Nov 7, 2025 10:38 AM ET
3-Hold of 5 3
B Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AZN 85.01 +1.24(1.48%)
Will AZN be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for AZN based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for AZN
Pre-Markets Improve on Big Earnings Morning
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
AZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Astrazeneca (AZN) Stock Slides as Market Rises: Facts to Know Before You Trade
Other News for AZN
AstraZeneca (AZN) Warns UK on Drug Spending Risks
AstraZeneca (AZN) Reports Positive Phase III Trial Results for Fasenra
AstraZeneca CEO warns U.K. faces generics-only future, Guardian reports
AstraZeneca CEO warns U.K. faces generics-only future, Guardian reports
AstraZeneca reports statistical significance in NATRON trial